Semintra is a drug owned by BOEHRINGER LNGELHEIM ANIMAL HEALTH USA, INC. It is protected by 2 US drug patents filed from 2028 to 2030. All patents are active. Details of Semintra’s patents and their expiration are given below.
| Drug Patent Number | Drug Patent Expiry | Status |
|---|---|---|
| US9308197 | 19 Feb, 2028 | Active |
Exclusivity Information
Semintra holds 1 exclusivity out of which 1 has expired. Details of Semintra's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| NCE | May 15, 2023 |
About Semintra
Semintra is a drug
owned by BOEHRINGER LNGELHEIM ANIMAL HEALTH USA, INC.
Semintra uses
Telmisartan as the active
ingredient.
Active Ingredient:
Semintra uses
Telmisartan as the active ingredient.
Check out other Drugs and Companies using
Telmisartan ingredient.